FDA's Revolving Door: Crawford Out, von Eschenbach In
This article was originally published in RPM Report
Executive Summary
National Cancer Institute director Andrew von Eschenbach has succeeded Lester Crawford as FDA commissioner. We spoke to three Wall streeters--two sell-side, one buy side--about what the succession means for investors.